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Abstract
Kikuchi–Fujimoto disease (KFD) is a rare, self-limiting disorder that typically affects the cervical lymph nodes (LNs). Although initially
described in young women, KFD also occurs in men. There are no reports on the clinical manifestations and characteristics of male
KFD patients. Therefore, this study was conducted to assess the incidence of KFD amongmales, as well as the most frequent clinical
characteristics of these patients. A retrospective, cross-sectional study was performed at a tertiary hospital of patients pathologically
conﬁrmed as having KFD from LN biopsy specimens. Clinical and laboratory data, and treatment outcomes of the enrolled patients,
were analyzed by gender. A total of 254 patients diagnosed with KFD were enrolled. There were 189 females and 65 males (2.9:1).
Themean age was 32.6±11.3 years. Compared to the female patients, the males hadmore frequent manifestations of fever (48% vs
67%, P=0.008), headache (9% vs 20%, P=0.013), bilateral lymphadenopathy (31% vs 46%, P=0.029), thrombocytopenia (14% vs
29%, P=0.014), elevated C-reactive protein (CRP) (35% vs 78.4%, P<0.001), elevated liver enzymes (15% vs 41%, P<0.001), and
elevated lactate dehydrogenase (LDH) (61% vs 80%, P=0.021). Male patients had fewer autoimmune features (9% vs 2%, P=
0.043) and fewer positive antinuclear antibodies (32% vs 10%, P=0.006). In this study, 25.6% of the enrolled patients were male,
with a 2.9:1 female-to-male sex ratio. Male patients showed a distinctive proﬁle characterized by a higher frequency of fever,
headache, bilateral lymphadenopathy, and thrombocytopenia, as well as elevated liver enzymes, CRP, and LDH.
Abbreviations: ANA = antinuclear antibody, AOSD = adult-onset Still disease, CKD = chronic kidney disease, CRP = C-reactive
protein, ESR = erythrocyte sedimentation rate, KFD = Kikuchi–Fujimoto disease, LDH = lactate dehydrogenase, LFT = liver function
test, LN = lymph node, MCD = mixed connective tissue disease, NSAID = nonsteroidal anti-inﬂammatory drugs, SLE = systemic
lupus erythematosus.
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Kikuchi–Fujimoto disease (KFD), also known as histiocytic
necrotizing lymphadenitis, was ﬁrst reported in Japan in
1972.[1–4] It is a rare cause of lymphadenopathy, characterized
by cervical lymphadenopathy, fever, and leukopenia, which is
usually clinically benign.[5] The pathogenesis of KFD remainsEditor: Giovanni Tarantino.
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1unknown, but an immune response of T cells and histiocytes to an
infectious agent is considered to be the most probable cause.[6]
KFD has been most frequently been reported in Asia,[7] but has
been identiﬁed in many ethnic groups in various countries.[8]
KFDmainly occurs at a young age and has been reported to occur
more frequently in women.[9–11] The male-to-female sex ratio
varies from 1:16 to 1:4.[9–13] The sex distribution is almost equal
in adult Asian populations, but among children aged 18 years or
younger, male predominance has been reported (8:3).[14]
Prior studies on the clinical manifestations and outcomes of
KFD have focused on females, and few studies exist on KFD
among young men. Furthermore, to the best of our knowledge,
there have been no larger scale reports on differences in clinical
manifestations by gender. Therefore, the aim of this study was to
identify the male incidence of KFD and investigate the clinical
manifestations and laboratory features that are more frequently
observed in male KFD patients.
2. Methods
2.1. Study design
A retrospective, observational cohort study was performed at a
2000-bed tertiary hospital in South Korea, from December 1995
to December 2014. Patients aged 18 years or older, with regional
or generalized lymphadenopathy, and compatible histologic
Jung et al. Medicine (2017) 96:11 Medicineﬁndings (histiocytes and lymphoid cell aggregates or subacute
necrotizing lymphadenopathy) in histology analyses from lymph
node (LN) biopsy specimens were deﬁned as KFD.[15] Patients
diagnosed with a concurrent malignant lymphoma or tuberculo-
sis were excluded from the study. Patients lacking imaging data
(computed tomography or ultrasonography of the neck) or
sufﬁcient medical records regarding their clinical symptoms were
also excluded. This study was approved by the ethics committee
of the Yonsei University College of Medicine Severance Hospital.
Informed consent was waived from all patients.
The following variables were assessed: demographic and
baseline clinical characteristics (age, gender, presence of
hypertension, diabetes, malignant disease, chronic kidney disease
[CKD], and autoimmune diseases), clinical signs and symptoms
at diagnosis (pain, fever, night sweats, sore throat, weight loss,
rash, myalgia, arthralgia, nausea, and headache), lymphadenop-
athy features (duration of onset, lesions [cervical, extracervical,
single, or multiple], size of the largest LN, laterality, and sites of
cervical involvement) and laboratory results (complete blood cell
counts, erythrocyte sedimentation rate [ESR], C-reactive protein
[CRP], liver function tests [LFTs], lactate dehydrogenase [LDH],
and antinuclear antibodies [ANAs]), and outcomes (treatment
options, cure or relapse, and all-cause mortality).2.2. Deﬁnitions
Patients with malignancy included those with a history of solid
organ cancer or hematologic malignancy at the time of KFD
diagnosis. Diabetes was deﬁned based on the American Diabetes
Association diagnostic criteria.[16] Hypertension was deﬁned in
patients with a systolic blood pressure of 140mmHg or more, or
a diastolic blood pressure of 90mm Hg or more, or taking
antihypertensive medication.[17] CKD was deﬁned as either
kidney damage or a decreased glomerular ﬁltration rate of less
than 60mL/min/1.73m2 for at least 3 months.[18] Autoimmune
disease was deﬁned in patients diagnosed with systemic lupus
erythematosus (SLE), adult-onset Still disease (AOSD), Sjögren
syndrome, or Behçet disease.
Fever was deﬁned as a temperature over 38.0 °C as an initial
symptom. A headache was deﬁned as symptoms lasting for more
than a week. Extracervical LN involvement was deﬁned as
involvement of the axillary, mesenteric, or inguinal LNs.Multiple
LN involvement was deﬁned as having multiple levels of cervical
lymphadenopathy. Relapse was deﬁned as pathologically proven
KFD on rebiopsy due to recurring symptoms of fever or
lymphadenopathy during a 3-month follow-up.
Leukopenia was deﬁned as a white blood cell count lower than
4000 cells/mL. Neutropenia was deﬁned as an absolute
neutrophil count of lower than 1500 cells/mL. Anemia was
deﬁned as having a hemoglobin level lower than 12g/dL.[11]
Thrombocytopenia was deﬁned as a platelet count below
150,000 cells/mL.[19] Elevated ESR was deﬁned as a level
exceeding 60mm/h.[11] Elevated CRP was deﬁned as a level
exceeding 8mg/L.[11] An abnormal LFTwas deﬁned as an alanine
aminotransferase level exceeding 40 IU/L.[11] Elevated LDH was
deﬁned as a level exceeding 500IU/L.[11]Figure 1. Patient inclusion algorithm.2.3. Data analysis
Normally distributed continuous variables are expressed as
means± standard deviation, and categorical variables are
presented as numbers and percentages. The statistical signiﬁcance
of the comparisons was assessed using a paired t test and the x22test. A P value <0.05 was considered statistically signiﬁcant.
Analyses were performed using SPSS software (ver. 23.0; SPSS
Inc., Chicago, IL).3. Results
A total of 284 patients were diagnosedwith KFD during the study
period. After excluding 30 patients (20 patients had no imaging
data, 7 had incomplete medical records, and 3 were diagnosed
with concurrent tuberculosis), 254 patients were ﬁnally enrolled
in this study (Fig. 1).
Of these patients, 25.6% (n=65) were male, and the female-to-
male sex ratio was 2.91:1. The mean age at diagnosis was 30.5±
11.0 years inmales and 30.0±9.3 years in females. There were no
signiﬁcant differences in age or underlying disease, except for
autoimmune diseases, between males and females. Seventeen
female subjects had been diagnosed with an autoimmune disease,
which showed a female predominance, as only 1 male patient had
a history of autoimmune disease (n=17 [9%] vs n=1 [2%], P=
0.043). There were no patients in this study who were diagnosed
with rheumatoid arthritis, systemic sclerosis, polymyositis/
dermatomyositis, or vasculitis. There was 1 patient who was
diagnosed with mixed connective tissue disease (MCD) (Table 1).
In this study, male patients experienced fever (n=90 [48%] vs
n=43 [67%], P=0.008) and headache (n=16 [9%] vs n=13
[20%], P=0.013) more frequently than females. The duration of
fever was shorter in male patients, with a mean duration of 8
days, compared to 13 days in females (P=0.014). Fever (67%),
tenderness on the affected LN (32%), and headache (20%) were
the most frequent symptoms experienced by male patients. Male
patients also had more frequent bilateral LN involvement
compared to females (n=59 [31%] vs n=30 [46%], P=
0.029). Cervical lymphadenopathy was seen in 95.7% of the
total subjects, with no difference observed between genders. The
duration of onset, or size, or site of cervical involvement also
showed no difference between the genders (Table 1).
Thrombocytopenia was more frequently observed in male
versus female patients (22 [14%] vs 17 [29%], P=0.014). Male
patients also had more frequent abnormal LFTs (21 [15%] vs 24
[41%], P<0.001), elevated serum LDH (62 [61%] vs 39 [80%],
Table 1
The baseline characteristics and clinical features of the patients.
Female (n=189) Male (n=65) P
Age, y 30.0±9.3 30.5±11.0 0.870
Underlying diseases (n, %)
Malignancy 11 (5.8) 5 (7.7) 0.592
Diabetes 1 (0.5) 0 (0) 1.000
Hypertension 2 (1.1) 0 (0) 1.000
CKD 0 (0) 1 (1.5) 0.256
Autoimmune disease 17 (9.0) 1 (1.5) 0.043
SLE 9 (4.8) 1 (1.5) 0.249
AOSD 3 (1.6) 0 (0) 0.572
Sjögren 3 (1.6) 0 (0) 0.572
Behçet 2 (1.1) 0 (0) 1.000
MCD 1 (0.5) 0 (0) 1.000
Clinical manifestation (n, %)
Pain 75 (40.1) 20 (31.7) 0.237
Fever (≥38.0 °C) 90 (48.1) 43 (67.2) 0.008
Fever duration, d 13±20.9 8±13.4 0.014
Night sweat 6 (3.2) 6 (9.2) 0.083
Sore throat 19 (10.2) 9 (13.8) 0.415
Weight loss (≥10%) 18 (9.6) 6 (9.2) 0.926
Rash 12 (6.4) 3 (4.6) 0.597
Myalgia 25 (13.4) 10 (15.4) 0.686
Arthralgia 12 (6.4) 2 (3.1) 0.311
Nausea 10 (5.3) 4 (6.2) 0.807
Headache 16 (8.6) 13 (20.0) 0.013
Lymphadenopathy (n, %)
Involved LN
One level cervical LN 179 (94.7) 64 (98.5) 0.200
Multiple levels of cervical LNs 176 (93.1) 62 (95.4) 0.517
Extracervical LNs
∗
29 (15.3) 17 (26.2) 0.051
Size, cm
<1 18 (9.5) 3 (4.6) 0.215
1–2 116 (61.4) 37 (56.9) 0.527
>2 50 (26.5) 24 (36.9) 0.109
Laterality
Left 64 (33.9) 18 (22.7) 0.359
Right 65 (34.4) 17 (26.2) 0.220
Both 59 (31.2) 30 (46.2) 0.029
Onset, mo
Less than 1 131 (69.3) 50 (76.9) 0.242
1–2 47 (24.9) 11 (16.9) 0.188
More than 2 10 (5.3) 4 (6.2) 0.793
Cervical site
Anterior triangle 17 (9.0) 4 (6.2) 0.473
Posterior triangle 155 (82.0) 54 (83.1) 0.846
Both triangles 17 (9.0) 7 (10.8) 0.673
Data are expressed as the mean± standard deviation or n (%). AOSD = adult onset Still disease, CKD
= chronic kidney disease, LN = lymph node, MCD = mixed connective tissue disease, SLE =
systemic lupus erythematosus.
∗
Extracervical LN: para-aortic, mesenteric lymph nodes.
Table 2
The laboratory ﬁndings of the patients.
Female (n=189) Male (n=65) P
Laboratory ﬁndings (n, %)
Leukopenia 86 (55.8) 33 (55.9) 0.991
Neutropenia 86 (55.8) 33 (55.9) 0.991
Anemia 44 (28.6) 13 (22.0) 0.335
Thrombopenia 22 (14.3) 17 (28.8) 0.014
Elevated ESR 107 (56.6) 41 (63.1) 0.362
ESR, mm/h, mean±SD 43.0±26.0 38.8±22.7 0.312
Elevated CRP 41 (35.0) 40 (78.4) <0.001
CRP, g/dL, mean±SD 17.2±35.2 41.6±1.6 0.003
Abnormal LFTs 21 (14.7) 24 (41.4) <0.001
Elevated LDH 62 (60.8) 39 (79.6) 0.021
ANA positivity 32 (31.7) 4 (9.8) 0.006
ANA = antinuclear antibody, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, LDH =
lactate dehydrogenase, LFT = liver function test.
Table 3
The treatment outcomes of the patients.
Female (n=189) Male (n=65) P
Treatment (n, %)
No treatment 67 (35.4) 24 (36.9) 0.831
Steroid 36 (19.0) 10 (15.4) 0.508
NSAIDs 67 (35.4) 19 (29.2) 0.361
Both 19 (10.1) 12 (18.5) 0.074
Relapse (n, %) 2 (1.1) 0 (0) 0.405
Death (n, %) 4 (2.1) 0 (0) 0.237
NSAID = nonsteroidal anti-inﬂammatory drug.
Jung et al. Medicine (2017) 96:11 www.md-journal.comP=0.021), and elevated CRP (41 [35%] vs 40 [78.4%], P<
0.001). However, ANA positivity was signiﬁcantly more frequent
in female patients (32 [32%] vs 4 [10%], P=0.006) (Table 2).
Regarding the ﬁnal outcomes, 35.8% of patients showed
spontaneous clinical improvement, that is, improvement without
treatment. Monotherapy, of steroids or nonsteroidal anti-
inﬂammatory drugs (NSAIDs), was administered to 18% and
33.8% of the patients, respectively; 12% of the patients received
both types of treatment. Pathologically proven relapse and
disease-related mortality occurred more frequently in female
patients, but there was no statistically signiﬁcant difference
between males and females (4 [2%] vs 0 [0%], P=0.237)
(Table 3).34. Discussion
In this study, the ratio of KFD-affected females to males was
2.9:1. A study by Seo et al,[14] of Korean individuals younger than
18 years of age, showed no difference in KFD incidence by
gender. However, Kang et al[20] reported a female-to-male sex
ratio of KFD of 1.32:1 among Korean children. This difference
may be explained by the age differences of the patients between
these studies, where the median ages were 13.2 and 12.45 years,
respectively. In 3 studies on adults, the ratios of affected females
to males were 4:1, 1.6:1, and 1.26:1, respectively.[9,10,12]
Among our male patients, fever (67%), tenderness on the
affected LN (32%), and headache (20%) were the most frequent
symptoms. Although tenderness of the affected site showed no
difference between genders, headache (20%) was more frequent
in male patients. Fever was also more frequent in males, with
67%of male patients presenting with fever as an initial symptom.
However, the total duration of fever was longer in female
patients, with a mean duration of 13±20.9 days. In a
retrospective review by Kucukardali et al[13] of 244 KFD patients
(in which 77% of the patients were female), fever (35%), fatigue
(7%), and joint pain (7%) were the most frequent symptoms. The
most common symptoms of the female patients in this study were
fever (48%), tenderness of the affected LN (40%), and myalgia
(13%). Arthralgia was present in 6% of the female patients,
similar to the results of the Kucukardali study.
A study conducted in the United States showed that 83% of
patients had localized lymphadenopathy, particularly of the
posterior cervical area.[12] In another study of 79 Chinese
patients, 97% presented with cervical lymphadenopathy, and
there was bilateral involvement in 18 (22%) patients.[21] In this
Jung et al. Medicine (2017) 96:11 Medicinestudy, 95.7% of patients presented with cervical lymphadenopa-
thy, most frequently in the posterior cervical triangle. In total,
46% of male patients had bilateral lymphadenopathy, while this
was seen in only 31% of the female patients. The results in this
study are similar to those of previous studies, in which KFD
commonly presented as posterior cervical lymphadenopathy, and
they show that male patients present with bilateral lymphade-
nopathy more frequently than females.
In this study, elevated LDH (80%), leukopenia (56%), elevated
CRP (78.4%), and elevated liver enzymes (41%) were the most
frequent laboratory ﬁndings in male patients. Furthermore,
thrombocytopenia, elevated liver enzymes, and LDH are all
markers of severe inﬂammation and were seen more frequently in
male patients. Keogh et al[22] reported a case of a young man
diagnosed with KFD who developed respiratory failure,
parotidomegaly, and thyroiditis, requiring intensive care unit
management. These ﬁndings suggest that KFD in males may be
more commonly associated with severe systemic inﬂammation
and presents as a more severe form of illness compared to that
seen in females. These ﬁndings are consistent with the results of
previous studies.[13]
An autoimmune mechanism is often proposed in KFD, since
many studies have described an association between KFD and
SLE.[23,24] In this study, SLE was present in 9 (5%) female
patients and 1 (2%) male patient. This shows that autoimmune
diseases are more frequent in females, which agrees with the
results of previous studies.[10] Since KFD and SLE share similar
sex and age proﬁles, that is, occur more often in young
females,[25] several studies recommend ANA testing in patients
initially diagnosed with KFD to exclude concomitant SLE.[10,12]
In this study, the ANA-positive rate was also higher among
females.
In the majority of patients, KFD is a benign, self-limiting
disease.[15] Our study results did not differ from those of previous
studies, with more than 35% of the patients showing a
spontaneous resolution without any speciﬁc treatment. Death
occurred in 4 female patients, and there was no KFD-related
mortality in the male patients. No male, and only 2 female,
patients experienced a single episode of relapse. Smith et al[26]
reported a female patient with 4 episodes of recurrent KFD over a
period of 18 years. However, as our study only enrolled patients
with histologically proven KFD, the recurrence rate may have
been underestimated.
There were several limitations to this study. First, it was
conducted retrospectively, and cases without sufﬁcient clinical
data on the symptoms were excluded. This may have resulted in a
reduced number of patients with KFD being enrolled. Second,
only cases that were histopathologically conﬁrmed at initial
diagnosis and recurrence were included. Those patients who were
very likely to have KFD based solely on their clinical data were
not included. Third, a total of 15 patients (12 patients on steroids;
6 for SLE, 2 for Sjogren disease, 1 for Behçet disease, 2 for AOSD,
1 for MCD, and 3 patients on NSAIDs due to SLE) already
receiving NSAIDs or steroids for treating autoimmune diseases
were included in the study, and this may have interfered with the
evaluation.
In conclusion, 25.6% of enrolled patients were males, with a
2.9:1 female-to-male sex ratio. Male patients showed a distinct
proﬁle characterized by a higher frequency of fever, headache,
bilateral lymphadenopathy, and thrombocytopenia, as well as
elevated liver enzymes, CRP, and LDH. Female patients4presented with autoimmune disorders and ANA positivity more
frequently.References
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